-
Innovation Ranking
NewInnovation Ranking – Canadian Natural Resources Ltd
Canadian Natural Resources Ltd (Canadian Natural) is an independent upstream oil and gas company. It carries out acquisition, exploration, development, production, marketing and sale of crude oil, natural gas and natural gas liquids (NGLs). The company’s product offering includes light and medium crude oil and NGLs, primary heavy crude oil, Pelican Lake heavy crude oil, bitumen (thermal oil), synthetic crude oil (SCO) and natural gas. Canadian Natural's operations are focused in North America, mostly in Western Canada; the UK portion...
-
Innovation Ranking
NewInnovation Ranking – Oil and Natural Gas Corp Ltd
Oil and Natural Gas Corp Ltd (ONGC) is an integrated energy company operating along the hydrocarbon value chain. It discovers, produces, refines, and markets oil and gas, and also manufactures petrochemicals. ONGC also carries out power generation and has considerable renewable energy operations. The company carries out refining operations through Mangalore Refinery and Petrochemicals Ltd and Hindustan Petroleum Corporation Ltd. It sells products to oil refining and gas marketing companies. In addition, the company conducts overseas operations through its subsidiary,...
-
Product Insights
Likelihood of Approval Analysis for Natural Killer Cell Lymphomas
Overview How likely is it that the drugs in Natural Killer Cell Lymphomas will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Natural Killer Cell Lymphomas Overview Natural killer (NK) cell lymphomas...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crenigacestat in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crenigacestat in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crenigacestat in Natural Killer Cell Lymphomas Drug Details: Crenigacestat...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sugemalimab in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sugemalimab in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sugemalimab in Natural Killer Cell Lymphomas Drug Details: Sugemalimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isatuximab in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isatuximab in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isatuximab in Natural Killer Cell Lymphomas Drug Details: Isatuximab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Natural Killer Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Natural Killer Cell Lymphomas Drug Details: Tipifarnib (Zarnestra)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Natural Killer Cell Lymphomas Drug Details: Cemiplimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Duvelisib in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Duvelisib in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Duvelisib in Natural Killer Cell Lymphomas Drug Details: Duvelisib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD30 in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD30 in Natural Killer Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD30 in Natural Killer Cell Lymphomas Drug Details: Gene therapy...